Though results of the SURPASS CVOT (a dedicated cardiovascular outcomes trial for Tirzepatide) are due to report in October 2024, the pre-specified data from SURPASS 1 to 5 and J-mono suggest that tirzepatide (mean assigned dose: 9.9 mg qw) might potentially decrease the risks of MACE and all-cause mortality in T2DM patients (as evidenced by HR of 0.80, although this did not reach statistical significance) [ 92 ].
1
—
—